Clinical Trial Update: Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults [Phase 1]

View source ↗

Summary

This clinical trial update reports completion of a Phase 1 study of a human bispecific antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) for HIV infection, evaluating …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC-HIVMAB0121-00-AB (CAP256J3LS)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infection | Phase 1 | Status: COMPLETED